Contineum Therapeutics, Inc.
CTNM
$11.01
$0.575.46%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -100.00% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -100.00% |
| SG&A Expenses | 62.55% | 81.99% | 97.89% | 85.18% | 55.92% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 56.21% | 70.99% | 52.50% | 50.03% | 46.57% |
| Operating Income | -56.21% | -70.99% | -624.55% | -416.57% | -314.36% |
| Income Before Tax | -66.71% | -79.23% | -354.54% | -282.38% | -251.02% |
| Income Tax Expenses | -- | -- | -- | -- | -126.35% |
| Earnings from Continuing Operations | -67.47% | -80.82% | -360.53% | -285.99% | -254.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -67.47% | -80.82% | -360.53% | -285.99% | -254.34% |
| EBIT | -56.21% | -70.99% | -624.55% | -416.57% | -314.36% |
| EBITDA | -56.29% | -71.12% | -613.76% | -411.19% | -310.80% |
| EPS Basic | 53.45% | 69.17% | 0.65% | -445.15% | -246.65% |
| Normalized Basic EPS | 70.79% | 78.14% | -122.43% | -148.03% | -175.26% |
| EPS Diluted | 53.45% | 69.17% | 60.33% | -214.58% | -10.14% |
| Normalized Diluted EPS | 70.79% | 78.14% | -611.05% | -523.21% | -734.99% |
| Average Basic Shares Outstanding | 96.48% | 239.94% | 980.37% | 736.63% | 487.85% |
| Average Diluted Shares Outstanding | 96.48% | 239.94% | 773.76% | 575.35% | 373.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |